Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymphoma, b-sejt - daganatellenes szerek - polivy kombinálva bendamustine, valamint rituximab kezelésére javallt, a felnőtt betegek relapszusos/refrakter diffúz nagy b-sejtes lymphoma (dlbcl), akik nem jelöltek haemopoetikus őssejt-transzplantációs. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

allos therapeutics ltd - pralatrexate - lymphoma, t-cell - daganatellenes szerek - kezelés perifériás t-sejtes lymphoma,.

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

celgene europe ltd. - romidepsin - lymphoma, non-hodgkin - daganatellenes szerek - kezelés perifériás t-sejtes lymphoma (ptcl),.

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymphoma, follicularis - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

eisai gmbh - bexaroten - lymphoma, t-cell, cutaneous - daganatellenes szerek - targretin kapszula szerepelnek a bőrtünetek előrehaladott cutan t-sejtes lymphoma (ctcl) betegek tűzálló legalább egy szisztémás kezelés kezelésére.

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - daganatellenes szerek - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Ευρωπαϊκή Ένωση - Ουγγρικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - daganatellenes szerek - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Ουγγαρία - Ουγγρικά - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

bastian-werk gmbh - hidroxietil szalicilát; kámfor -